- Biden Administration to Back Lifting of COVID Vaccine Patents
- Health Highlights: May 6, 2021
- When Black Americans Encounter Police Violence, High Anxiety Often Follows
- Real-World Studies Show Pfizer Vaccine Shields Against COVID Variants
- Drug Saxenda Aids Weight Loss — But You Should Exercise, Too
- Israel Study: Pfizer Vaccine Gives 95% Protection Against Illness, Hospitalization & Death
- Better Access to Birth Control Boosts School Graduation Rates
- What Was Antarctic Explorer Ernest Shackleton’s Mystery Illness?
- Many Consumers Misunderstand Those ‘Best Before’ Food Labels
- U.S. COVID Outlook Shows Big Improvement by July
Flu Vaccine for Seniors Approved
THURSDAY, Dec. 24Fluzone High-Dose, a seasonal flu vaccine for people 65 and older, has been approved by the U.S. Food and Drug Administration, the agency said in a news release.
Seniors are at highest risk for complications of seasonal flu, including hospitalization and death. The Fluzone High-Dose vaccine, designed to prevent infection with influenza subtypes A and B, was given accelerated approval as a product designed to prevent serious or life-threatening disease. As part of the approval, manufacturer Sanofi Pasteur is required to “conduct further studies to verify that [the vaccine] will decrease seasonal influenza after vaccination,” the FDA said.
Because of the vaccine’s higher potency, mild side effects were reported more frequently compared with Sanofi’s standard-strength Fluzone vaccine, the agency said. These included pain, injection-site redness and swelling, headache, muscle ache and fever.
People who are sensitive to egg products or who have had life-threatening reactions to prior flu shots shouldn’t be vaccinated with Fluzone High-Dose, the FDA said.
More information
The U.S. Centers for Disease Control and Prevention has more about flu vaccination.
Source: HealthDay
